Evidence map›Paper›PMID 33611825›Full record

ArticleThe Kaohsiung journal of medical sciences2021

LINC01315 promotes the aggressive phenotypes of papillary thyroid cancer cells by sponging miR-497-5p.

Jian Ren, Feng-Jiao Zhang, Jing-Hong Wang, Jian-Dong Tang

Abstract read
In one paragraph

Article in The Kaohsiung journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. NScientific reports · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jian RenDepartment of Endocrinology, Zhengzhou Central Hospital Affiliated to ZhengZhou University, Zhengzhou, China.
Feng-Jiao ZhangDepartment of Endocrinology, Zhengzhou Central Hospital Affiliated to ZhengZhou University, Zhengzhou, China.
Jing-Hong WangDepartment of Endocrinology, Zhengzhou Central Hospital Affiliated to ZhengZhou University, Zhengzhou, China.
Jian-Dong TangDepartment of Endocrinology, Zhengzhou Central Hospital Affiliated to ZhengZhou University, Zhengzhou, China.ORCID https://orcid.org/0000-0002-9138-4323

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysregulation of the long intergenic noncoding RNA 01315 (LINC01315) has recently been demonstrated in cancer. However, the role of LINC01315 in papillary thyroid cancer (PTC) has not been determined. We attempted to determine the function of LINC01315 in PTC. The levels of LINC01315 were higher in thyroid carcinoma tissues and cell lines compared with that in noncancerous tissues or normal cells, respectively. LINC01315 knockdown significantly inhibited the in vitro colony formation and invasion of PTC cells. Upregulation of LINC01315 produced opposite effects. Bioinformatic analysis and luciferase reporter assays indicated direct binding of miR-497-5p to LINC01315. Gain- and loss-of-function assays indicated that miR-497-5p acts as a suppressive miRNA in PTC. Furthermore, LINC01315 facilitated the growth and invasion of PTC cells by sponging miR-497-5p. Our results demonstrated the critical role of the LINC01315-miR-497-5p axis in the growth and invasion of PTC cells.

Indexed as

AdultCell Line, TumorCell ProliferationCell SurvivalComputational BiologyFemaleHumansLuciferasesMaleMicroRNAsMiddle AgedNeoplasm InvasivenessPhenotypeRNA, Long NoncodingThyroid Cancer, PapillaryThyroid NeoplasmsLuciferasesMicroRNAsMIRN497 microRNA, humanRNA, Long NoncodinginvasionLINC01315MiR-497-5ppapillary thyroid cancer

Identifiers

PMID33611825
PMCPMC11896402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.